NEW YORK, Dec. 18, 2014 /PRNewswire/ -- MLV & Co. announced today that Dr. Raghuram Selvaraju and Ken Trbovich have joined the firm's equity research team as Senior Analysts covering the rapidly growing biotechnology, specialty pharmaceuticals, and diagnostics sectors.
"Recruiting Dr. Selvaraju and Mr. Trbovich is another example of MLV's commitment to bringing highly regarded experience and expertise to our leading healthcare research platform," said Patrice McNicoll, CEO and Founding Partner of MLV & Co. "Dr. Selvaraju and Mr. Trbovich both have established track records in providing exceptional value to institutional and corporate clients."
Dr. Selvaraju joins MLV from Aegis Capital, where he was Managing Director and Head of Healthcare Equity Research. With over 15 years of experience in his coverage sector, Dr. Selvaraju has been ranked on The Wall Street Journal's "Best on the Street Survey" and StarMine for earnings accuracy since 2010. His research is widely quoted in publications such as The Wall Street Journal and Barron's and has been featured on Bloomberg TV and CNBC. Dr. Selvaraju began his career in biotechnology at the Serono Pharmaceutical Research Institute in Geneva.
Mr. Trbovich joins MLV with over a decade of experience covering the healthcare sector, and previously held Senior Analyst positions at RBC Capital Markets, C.K. Cooper and Company, and C.E. Unterberg, Towbin. He has been recognized by The Wall Street Journal and Forbes Magazine as an "All-Star Analyst" for his research coverage in the pharmaceutical sector.
"MLV's healthcare platform enables our clients to benefit from the significant upside potential of many dynamic, emerging healthcare companies," said Dean Colucci, President of MLV & Co. "These two outstanding analysts are key additions to our team and will apply their deep industry expertise to further our goal of providing the most relevant and insightful research for our clients."
About MLV & Co:
MLV & Co., an MLV Financial company, is an independent full service investment bank and institutional broker dealer. MLV is focused on providing creative capital raising solutions to growth-oriented companies in healthcare, real estate, financials, energy & natural resources, technology and other "capital-intensive" sectors.
MLV is the leader in capital raised for healthcare companies through At-the-Market Issuance ("ATM"), comprising 42% of all capital raised At-the-Market in the industry. The group is also recognized for:
- 100+ healthcare deals transacted since 2010
- $3+ billion of equity deals filed
- $960+ million raised via ATM
- $800+ million raised via traditional follow-on equity offerings
- Introduced the first publicly listed perpetual preferred in healthcare (Feb 2014)
- Research coverage on 45 biotechnology, specialty pharmaceuticals, diagnostics, and medical devices companies
MLV is a member of FINRA, NASDAQ, and the SIPC.
MLV & Co News Alerts
Dukas Public Relations
SOURCE MLV & Co.